.jpeg)
2026-05-19 07:04:42
This article details the medication precautions and risk management strategies for the KRAS G12C targeted inhibitor Adagrasib in women of childbearing age, pregnant and lactating women, elderly patients, and patients with underlying comorbidities.
2026-05-18 04:21:15
Olutasidenib (Rezlidhia) is an oral IDH1 mutation inhibitor developed by Rigel Pharmaceuticals. Approved by the FDA in 2022, it is used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring IDH1 mutations. With definite efficacy and good tolerability, it provides a precise targeted treatment option for such patients.
2026-05-18 04:06:05
Capmatinib, a highly selective MET inhibitor, demonstrates transformative efficacy in METex14-mutated NSCLC. Pivotal GEOMETRY data show significant tumor shrinkage and survival improvement, particularly in brain metastases. Global accessibility through originator and generic options empowers patients, while ongoing combo therapies and resistance research expand future horizons.
2026-05-15 02:34:50
Beyond its traditional TKI role, Cabozantinib is reshaping cancer care as a core agent across RCC, RAI-R DTC, HCC, and NETs. This article dissects its expanding indications, synergistic combination strategies, side effect management, and global access dynamics, offering actionable insights for patients and clinicians in the Asia-Pacific and international communities.
2026-05-12 03:08:03
Tucatinib, an oral TKI developed by Seagen, selectively targets HER2 to inhibit cancer cell growth. Approved by FDA in 2020 for advanced HER2+ breast cancer (including brain metastases) and expanded to RAS-wildtype HER2+ CRC in 2023. This treatment, combined with trastuzumab and capecitabine, significantly prolongs survival and improves outcomes. This article details indications, dosing, precautions, and safety profiles for informed clinical use.
2026-05-11 02:36:52
Pralsetinib, a highly selective RET inhibitor, is revolutionizing treatment for RET fusion-positive NSCLC and MTC. This article delves into its mechanism, clinical data, administration guidelines, and global accessibility, offering essential insights for patients and clinicians.
2026-04-30 04:14:23
This article details the mechanism of action, precise indications, eligible patient populations, and clinical value of elacestrant, analyzing its unique advantages and application boundaries in the treatment of endocrine-resistant hormone receptor-positive breast cancer.
2026-04-29 05:05:24
Selpercatinib is a highly selective RET kinase inhibitor indicated for the treatment of multiple advanced solid tumors associated with RET gene alterations, including non-small cell lung cancer, medullary thyroid cancer, and RET fusion-positive thyroid cancer. This guide provides detailed information on its indications, recommended dosage, dosage adjustments for special populations, important safety warnings, and drug interactions.
2026-04-28 04:44:27
This article provides a comprehensive overview of the approved indications, standard dosages for adults and children, administration methods, missed dose and vomiting management principles, as well as dose adjustments for special populations and adverse reaction management of the targeted drug entrectinib.
2026-04-28 04:28:10
This article provides a detailed analysis of the characteristics, mechanisms, high-risk factors, and clinical management points of bleeding risk associated with tepotinib in the treatment of MET-mutated non-small cell lung cancer, helping patients and healthcare professionals scientifically evaluate medication safety.
2026-04-28 04:21:32
This article systematically compares the mechanisms of action, clinical efficacy, side effect profiles, and applicable populations of lomustine and temozolomide, two alkylating antineoplastic agents, providing professional reference for treatment selection in patients with glioma and other tumors.
2026-04-28 03:25:11
This article provides a detailed analysis of the mechanisms of action and clinical therapeutic positioning of tepotinib and osimertinib, exploring the theoretical basis, research progress, and safety considerations of their combination therapy for patients with non-small cell lung cancer.
